Abstract:Oluwasolape Olawore, 1 Lindsey E Turner, 2, 3 Michael D Evans, 3 Steven G Johnson, 4 Jared D Huling, 2 Carolyn T Bramante, 5 John B Buse, 6 Til Stürmer 1 On behalf of the N3C Consortium 1 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2 Division of Biostatistics and Health Data Science, University of Minnesota School of Public Health, Minneapolis, MN, USA; 3 Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN, USA; 4 Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA; 5 Division of General Internal Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA; 6 Division of Endocrinology, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA Correspondence: Oluwasolape Olawore, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, McGavran-Greenberg Hall, 135 Dauer Drive, Chapel Hill, NC, 27599, USA, Email Background: Observed activity of metformin in reducing the risk of severe COVID-19 suggests a potential use of the anti-hyperglycemic in the prevention of post-acute sequelae of SARS-CoV-2 infection (PASC). We assessed the 3-month and 6-month risk of PASC among patients with type 2 diabetes mellitus (T2DM) comparing metformin users to sulfonylureas (SU) or dipeptidyl peptidase-4 inhibitors (DPP4i) users. Methods: We used de-identified patient level electronic health record data from the National Covid Cohort Collaborative (N3C) between October 2021 and April 2023. Participants were adults ≥ 18 years with T2DM who had at least one outpatient healthcare encounter in health institutions in the United States prior to COVID-19 diagnosis. The outcome of PASC was defined based on the presence of a diagnosis code for the illness or using a predicted probability based on a machine learning algorithm. We estimated the 3-month and 6-month risk of PASC and calculated crude and weighted risk ratios (RR), risk differences (RD), and differences in mean predicted probability. Results: We identified 5596 (mean age: 61.1 years; SD: 12.6) and 1451 (mean age: 64.9 years; SD 12.5) eligible prevalent users of metformin and SU/DPP4i respectively. We did not find a significant difference in risk of PASC at 3 months (RR = 0.86 [0.56; 1.32], RD = − 3.06 per 1000 [− 12.14; 6.01]), or at 6 months (RR = 0.81 [0.55; 1.20], RD = − 4.91 per 1000 [− 14.75, 4.93]) comparing prevalent users of metformin to prevalent users of SU/ DPP4i. Similar observations were made for the outcome definition using the ML algorithm. Conclusion: The observed estimates in our study are consistent with a reduced risk of PASC among prevalent users of metformin, however the uncertainty of our confidence intervals warrants cautious interpretations of the results. A standardized clinical definition of PASC is warranted for thorough evaluation of the effectiveness of therapies under assessment for the prevention of PASC. Plain Language Summary: Previous research suggests that metformin, due to its anti-viral, anti-inflammatory, and anti-thrombotic properties may reduce the risk of severe COVID-19. Given the shared etiology of COVID-19 and the post-acute sequelae of SARS-CoV-2 (PASC), and the proposed inflammatory processes of PASC, metformin may also be a beneficial preventive option. We investigated the benefit of metformin for PASC prevention in a population of type 2 diabetes mellitus patients with a COVID-19 diagnosis who were on metformin or two other anti-hyperglycemic medications prior to infection with SARS-CoV-2. Our results were consistent with a reduction in the risk of PASC with the use of metformin, however, the imprecise confidence intervals obtained warrants further investigation of this association of the potential beneficial effect of metformin for preventing PASC in patients with medication-managed diabetes. Keywords: COVID-19, Long COVID, Type 2 diabetes Mellitus, Metformin Post-acute sequelae of SARS-CoV-2 infection (PASC) is an emerging illness following mild or severe SARS-CoV-2 infection. 1 Although the true burden of the condition in the population has not been well characterized, incidence ranges of 8% to 40% have been reported from electronic health record (EHR) data. 1–4 The symptoms associated with PASC are diverse and can affect multiple organ systems. 1,5–9 Symptoms reported have included fatigue, shortness of breath, cognitive impairment, chest pain, -Abstract Truncated-

Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19

SSRI use during acute COVID-19 and risk of long COVID among patients with depression

Negative Prognostic Associations of Selective Serotonin Reuptake Inhibitors Use in Hospitalized COVID-19 Patients and Potential Contribution of Cardiovascular Comorbidities

Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use

No reduced serum serotonin levels in patients with post-acute sequelae of COVID-19

Serotonin reduction in post-acute sequelae of viral infection

Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies

Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation

Effect of the Early Administration of Selective Serotonin Reuptake Inhibitors on the Time Course of Poststroke Fatigue: A 2-Year Longitudinal Study

Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial

Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study

[P3–032]: SSRI USE ASSOCIATED WITH REDUCED AMYLOID BURDEN IN PERSONS WITH COMBAT‐RELATED PTSD: PRELIMINARY FINDINGS FROM ADNI‐DOD

1134 Post-acute Sequelae SARS CoV-2 Related Sleep Study and Symptom-based Factors Associated with Sleep Disturbances

Association of post-COVID phenotypic manifestations with new-onset psychiatric disease

Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)

The effect of selective serotonin reuptake inhibitors on cognitive impairment in patients with depression: A prospective, multicenter, observational study

Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID-19, analytical cross-sectional study

Insight into potential Long COVID effects: antidepressant use in post SARS-CoV-2 Infection scenarios. A Multiregional Nested Case-Control Study

Effect of background therapy with Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents on COVID-19 outcomes

Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes Mellitus on Anti-Hyperglycemic Medications

1135 Predictors of Post-COVID Clinical and Cognitive Consequences